Restem-L
Idiopathic Inflammatory Myopathy (IIM)
Key Facts
About Restem
Restem is a clinical-stage biotech advancing a dual-platform approach in cell therapy. Its lead platform, Restem-L, utilizes Umbilical Cord Lining Modified Progenitor Cells (UMPCs) for autoimmune disorders and is preparing for Phase 2/3 trials in Idiopathic Inflammatory Myopathy with FDA Fast Track and Orphan Drug designations. The company also has an activated Natural Killer (aNK) cell program targeting cellular senescence in age-related diseases and possesses end-to-end manufacturing capabilities.
View full company profileAbout Restem
Restem is a clinical-stage biotech advancing a dual-platform approach in cell therapy. Its lead platform, Restem-L, utilizes Umbilical Cord Lining Modified Progenitor Cells (UMPCs) for autoimmune disorders and is preparing for Phase 2/3 trials in Idiopathic Inflammatory Myopathy with FDA Fast Track and Orphan Drug designations. The company also has an activated Natural Killer (aNK) cell program targeting cellular senescence in age-related diseases and possesses end-to-end manufacturing capabilities.
View full company profileAbout Restem
Restem is a clinical-stage biotech advancing a dual-platform approach in cell therapy. Its lead platform, Restem-L, utilizes Umbilical Cord Lining Modified Progenitor Cells (UMPCs) for autoimmune disorders and is preparing for Phase 2/3 trials in Idiopathic Inflammatory Myopathy with FDA Fast Track and Orphan Drug designations. The company also has an activated Natural Killer (aNK) cell program targeting cellular senescence in age-related diseases and possesses end-to-end manufacturing capabilities.
View full company profile